You are here

Tecentriq

ASCO18: Tecentriq scores again in lung cancer, but Keytruda looms in background

ASCO18: Tecentriq scores again in lung cancer, but Keytruda looms in background

Biopharma Dive

advanced squamous non-small cell lung cancer

Flag link:

Exelixis Expands Ph Ib Immunotherapy Trial to Include Additional Patients with Locally Advanced or Metastatic Solid Tumors

Exelixis Expands Ph Ib Immunotherapy Trial to Include Additional Patients with Locally Advanced or Metastatic Solid Tumors

CP Wire

clinical trials

Flag link:

Exelixis Expands Ph Ib Immunotherapy Trial to Include Additional Patients with Locally Advanced or Metastatic Solid Tumors

Flag link:

Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results

Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results

Xconomy

clinical trials

Flag link:

Roche’s Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers

Roche’s Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers

Endpoints

non-squamous non-small cell lung cancer

Bristol-Myers Squibb

Flag link:

FDA warns of decreased survival in 2 studies of Keytruda, Tecentriq

FDA warns of decreased survival in 2 studies of Keytruda, Tecentriq

Biopharma Dive

clinical trials

Flag link:

Roche Tecentriq and Cotellic Combination Fails Ph III Trial in Colorectal Cancer

Roche Tecentriq and Cotellic Combination Fails Ph III Trial in Colorectal Cancer

CP Wire

colorectal cancer

Flag link:

Roche Tecentriq and Cotellic Combination Fails Ph III Trial in Colorectal Cancer

Flag link:

FDA promises Roche a snap decision on Tecentriq triple for frontline lung cancer as it falls even further behind Merck, Bristol-Myers

FDA promises Roche a snap decision on Tecentriq triple for frontline lung cancer as it falls even further behind Merck, Bristol-Myers

Endpoints

Flag link:

Roche halts enrollment in a PhII combo study of Tecentriq and Cotellic in wake of several patient deaths

Roche halts enrollment in a PhII combo study of Tecentriq and Cotellic in wake of several patient deaths

Endpoints

clinical trials

Flag link:

Roche's Avastin could get a boost with Tecentriq's second lung cancer win this week

Roche's Avastin could get a boost with Tecentriq's second lung cancer win this week

Fierce Pharma

Flag link:

Roche's Tecentriq cocktail notches another lung cancer success

Roche's Tecentriq cocktail notches another lung cancer success

Yahoo/Reuters

clinical trials

Flag link:

Roche's Tecentriq triumphs in squamous lung cancer. Can it make its mark against Merck?

Roche's Tecentriq triumphs in squamous lung cancer. Can it make its mark against Merck?

Fierce Pharma

squamous non-small cell lung cancer

Flag link:

In wake of Tecentriq bladder cancer bust and lost market share, Roche tries Tesaro combo

In wake of Tecentriq bladder cancer bust and lost market share, Roche tries Tesaro combo

Fierce Pharma

PARP inhibitors

Flag link:

Roche hails another PhIII win on Tecentriq combo, reports promising kidney cancer data

Roche hails another PhIII win on Tecentriq combo, reports promising kidney cancer data

Endpoints

Flag link:

Roche's latest Tecentriq results shed little light on the lung cancer market race: analyst

Roche's latest Tecentriq results shed little light on the lung cancer market race: analyst

Fierce Pharma

Flag link:

Roche's Tecentriq combo cuts risk of lung cancer progression

Roche's Tecentriq combo cuts risk of lung cancer progression

BioPharma Dive

Flag link:

Roche Gains Ground on Rivals With Drug Combo’s Success in Lung Cancer

Roche Gains Ground on Rivals With Drug Combo’s Success in Lung Cancer

Xconomy

Flag link:

Roche's Tecentriq cedes bladder-cancer share to Keytruda in wake of trial misfire

Roche's Tecentriq cedes bladder-cancer share to Keytruda in wake of trial misfire

Fierce Pharma

Flag link:

Most new cancer meds haven't proved they can improve or extend lives: study

Most new cancer meds haven't proved they can improve or extend lives: study

Fierce Pharma

Flag link:

Pages